Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation

Gianluigi Forloni, Azdrey Bidzinski, Rossella Fusi, Herbert Ladinsky, Silvana Consolo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The ergot derivatives, bromocriptine, lisuride and quinpirole (Ly-171555), activators of D-2 receptors, increased striatal acetylcholine (ACh) content by about 40% and induced a 30% inhibition of ACh evoked release from striatal slices, similar to the effects of the dopaminergic agonist apomorphine. These actions were a consequence of dopaminergic activation since they were antagonized by pretreatment with the neuroleptic agent, pimozide. In contrast, pretreatment with L-sulpiride (100 mg/kg), a specific antagonist for the D-2 dopaminergic receptor only, prevented the rise of ACh levels induced by apomorphine or quinpirole but did not interfere with the lisuride- or bromocriptine- induced ACh increases. Similarly, inhibition of the ACh evoked release produced by lisuride (3ωM) was prevented by pimozide (1mg/kg) but not by pretreatment with L-sulpiride. Addition of L-sulpiride (5ωM) to the Krebs solution had no effect on the inhibition of ACh-evoked release induced by lisuride, but a lower concentration (1ωM) antagonized the inhibition induced by quinpirole. Lisuride and bromocriptine responses were both insensitive to sulpiride. These results are discussed in terms of different interaction with the dopaminergic D-2 receptors by the drugs studied.

Original languageEnglish
Pages (from-to)1717-1723
Number of pages7
JournalLife Sciences
Volume41
Issue number14
DOIs
Publication statusPublished - Oct 5 1987

Fingerprint

Corpus Striatum
Lisuride
Cholinergic Agents
Acetylcholine
Sulpiride
Chemical activation
Quinpirole
Bromocriptine
Pimozide
Apomorphine
Drug Receptors
Dopamine Agonists
Antipsychotic Agents
Derivatives

ASJC Scopus subject areas

  • Pharmacology

Cite this

Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation. / Forloni, Gianluigi; Bidzinski, Azdrey; Fusi, Rossella; Ladinsky, Herbert; Consolo, Silvana.

In: Life Sciences, Vol. 41, No. 14, 05.10.1987, p. 1717-1723.

Research output: Contribution to journalArticle

Forloni, Gianluigi ; Bidzinski, Azdrey ; Fusi, Rossella ; Ladinsky, Herbert ; Consolo, Silvana. / Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation. In: Life Sciences. 1987 ; Vol. 41, No. 14. pp. 1717-1723.
@article{6d27e46addfb49a4b0a82a6c92785240,
title = "Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation",
abstract = "The ergot derivatives, bromocriptine, lisuride and quinpirole (Ly-171555), activators of D-2 receptors, increased striatal acetylcholine (ACh) content by about 40{\%} and induced a 30{\%} inhibition of ACh evoked release from striatal slices, similar to the effects of the dopaminergic agonist apomorphine. These actions were a consequence of dopaminergic activation since they were antagonized by pretreatment with the neuroleptic agent, pimozide. In contrast, pretreatment with L-sulpiride (100 mg/kg), a specific antagonist for the D-2 dopaminergic receptor only, prevented the rise of ACh levels induced by apomorphine or quinpirole but did not interfere with the lisuride- or bromocriptine- induced ACh increases. Similarly, inhibition of the ACh evoked release produced by lisuride (3ωM) was prevented by pimozide (1mg/kg) but not by pretreatment with L-sulpiride. Addition of L-sulpiride (5ωM) to the Krebs solution had no effect on the inhibition of ACh-evoked release induced by lisuride, but a lower concentration (1ωM) antagonized the inhibition induced by quinpirole. Lisuride and bromocriptine responses were both insensitive to sulpiride. These results are discussed in terms of different interaction with the dopaminergic D-2 receptors by the drugs studied.",
author = "Gianluigi Forloni and Azdrey Bidzinski and Rossella Fusi and Herbert Ladinsky and Silvana Consolo",
year = "1987",
month = "10",
day = "5",
doi = "10.1016/0024-3205(87)90599-6",
language = "English",
volume = "41",
pages = "1717--1723",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation

AU - Forloni, Gianluigi

AU - Bidzinski, Azdrey

AU - Fusi, Rossella

AU - Ladinsky, Herbert

AU - Consolo, Silvana

PY - 1987/10/5

Y1 - 1987/10/5

N2 - The ergot derivatives, bromocriptine, lisuride and quinpirole (Ly-171555), activators of D-2 receptors, increased striatal acetylcholine (ACh) content by about 40% and induced a 30% inhibition of ACh evoked release from striatal slices, similar to the effects of the dopaminergic agonist apomorphine. These actions were a consequence of dopaminergic activation since they were antagonized by pretreatment with the neuroleptic agent, pimozide. In contrast, pretreatment with L-sulpiride (100 mg/kg), a specific antagonist for the D-2 dopaminergic receptor only, prevented the rise of ACh levels induced by apomorphine or quinpirole but did not interfere with the lisuride- or bromocriptine- induced ACh increases. Similarly, inhibition of the ACh evoked release produced by lisuride (3ωM) was prevented by pimozide (1mg/kg) but not by pretreatment with L-sulpiride. Addition of L-sulpiride (5ωM) to the Krebs solution had no effect on the inhibition of ACh-evoked release induced by lisuride, but a lower concentration (1ωM) antagonized the inhibition induced by quinpirole. Lisuride and bromocriptine responses were both insensitive to sulpiride. These results are discussed in terms of different interaction with the dopaminergic D-2 receptors by the drugs studied.

AB - The ergot derivatives, bromocriptine, lisuride and quinpirole (Ly-171555), activators of D-2 receptors, increased striatal acetylcholine (ACh) content by about 40% and induced a 30% inhibition of ACh evoked release from striatal slices, similar to the effects of the dopaminergic agonist apomorphine. These actions were a consequence of dopaminergic activation since they were antagonized by pretreatment with the neuroleptic agent, pimozide. In contrast, pretreatment with L-sulpiride (100 mg/kg), a specific antagonist for the D-2 dopaminergic receptor only, prevented the rise of ACh levels induced by apomorphine or quinpirole but did not interfere with the lisuride- or bromocriptine- induced ACh increases. Similarly, inhibition of the ACh evoked release produced by lisuride (3ωM) was prevented by pimozide (1mg/kg) but not by pretreatment with L-sulpiride. Addition of L-sulpiride (5ωM) to the Krebs solution had no effect on the inhibition of ACh-evoked release induced by lisuride, but a lower concentration (1ωM) antagonized the inhibition induced by quinpirole. Lisuride and bromocriptine responses were both insensitive to sulpiride. These results are discussed in terms of different interaction with the dopaminergic D-2 receptors by the drugs studied.

UR - http://www.scopus.com/inward/record.url?scp=0023552355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023552355&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(87)90599-6

DO - 10.1016/0024-3205(87)90599-6

M3 - Article

C2 - 2958667

AN - SCOPUS:0023552355

VL - 41

SP - 1717

EP - 1723

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 14

ER -